益赛普联合甲氨蝶呤治疗类风湿关节炎的临床分析

Therapeutic effect of etanercept combined methotrexate on rheumatoid arthritis

目的:研究益赛普联合甲氨蝶呤治疗类风湿关节炎(RA)的临床疗效。方法:联合治疗组38例RA患者口服甲氨蝶呤15mg/周,同时皮下注射益赛普25mg/次,每周2次;对照组患者40例服相同剂量的甲氨蝶呤。治疗3个月后对两组的临床症状及实验室指标改善情况进行评价。结果:两组在缓解关节疼痛、减轻关节肿胀等方面均有良好的效果,联合治疗组优于对照组;两组治疗后血沉(ESR)、C反应蛋白(CRP)、类风湿因子(RF)均明显降低,且联合治疗组优于对照组。结论:益赛普联合甲氨蝶呤治疗RA疗效确切,且明显优于单用甲氨蝶呤。

Objective： To study the clinical efficacy of etanercept combined with methotrexate on patients with rheumatoid arthritis. Methods： The combination group （38 cases） was treated by oral methotrexate 15mg once a week plus subcutaneous injection of etanercept 25rag twice a week; the control group （40 cases） was treated by methotrexate only. After 3 months of treatment, the clinical symptoms and laboratory parameters of the two groups were evaluated. Results： Both groups had good effects on pain relief and reduction of swelling of joints, but the combination group showed better effects than the control group （P〈0.05）.The erythrocyte sedimentation rate （ESR）, C-reactive protein （CRP）,and rheumatoid factor （RF） were significantly more reduced in the combination group than in the control group（P〈0.05）. Conclusion： The combination of etanercept and methotrexate in the treatment of rheumatoid arthritis is significantly superior to methotrexate alone.